2023
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis
Hwang E, Abdelghaffar M, Shields B, Damsky W. Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis. JID Innovations 2023, 3: 100220. PMID: 37719661, PMCID: PMC10500476, DOI: 10.1016/j.xjidi.2023.100220.Peer-Reviewed Original ResearchDisease pathogenesisCutaneous granulomatous disordersLow-quality evidenceRepository corticotropin injectionOutcome of treatmentImmunomodulatory medicationsPulmonary sarcoidosisCutaneous sarcoidosisGranulomatous disorderNecrobiosis lipoidicaCorticotropin injectionMacrophage accumulationGranuloma annulareGranulomatous diseaseCutaneous granulomatous diseasesTargeted therapyDrug AdministrationMolecular pathogenesisNew treatmentsSystematic reviewPathogenesisTherapyDistinct diseasesTherapeutic innovationsDiseaseDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosis. Journal Of The American Academy Of Dermatology 2023, 90: 885-908. PMID: 37516359, DOI: 10.1016/j.jaad.2023.02.072.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsDiHS/DRESSClinicopathological featuresSystemic symptomsDrug reactionsDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromePart I. EpidemiologyVisceral organ involvementCutaneous adverse reactionsRisk of relapseHypersensitivity syndromeOrgan involvementI. EpidemiologyOrgan dysfunctionSignificant morbidityAutoimmune diseasesAdverse reactionsDrug exposureT cellsCommon triggerImmune systemPathogenesisEosinophiliaMedical education activities
2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesis